**COE Learning Network:** Drug Adulterants

**Presenters:** Katie Holler; Julie Brewer

**Date and Time:** 11/2/2022-12:00-1:15 pm

**Location:** Virtual Training (on Zoom)

**Host:** University of Pittsburgh, School of Pharmacy, Program and Evaluation Unit (PERU)

**Target Audience:** Centers of Excellence Leadership and Staff

**Training Objectives:**

* Define drug adulterants
* Identify common opioid adulterants
* Discuss the surveillance for adulterants in Pennsylvania ​
* Describe the basics of xylazine​
* Identify the signs of use, treatment, and physical effects of xylazine

**Agenda:**

1. Welcome, Introductions, Training Objectives
2. Drug Adulterants Overview
   1. Categories of adulterants
   2. Definition of adulterants
   3. List common opioid adulterants
   4. Fentanyl
3. Surveillance for Adulterants
   1. Current surveillance in PA
   2. Best practices
4. Xylazine Overview
   1. Xylazine basics
   2. Xylazine prevalence
   3. Effects of xylazine
   4. Signs of use
   5. Treatment
5. Questions

**Post Test Questions:**

1. Some classifications of substances commonly found in the illicit drug supply include (check all that apply):
   1. **Dilutants**
   2. **Microbiological contaminants**
   3. Radioactive contaminants
   4. **Substitutes**
2. True or **False**: Tests for all substances are regularly conducted by county coroners after a suspected drug overdose.
3. Xylazine entered the illicit drug market through:
   1. Illicit production
   2. Prescription diversion
   3. **Veterinary routes**
   4. Overseas sources
4. True or **False**: If you suspect an overdose of xylazine, you should not administer naloxone.

**References:**

* Bettigole, C., Franklin, F., Hom, J., (2021, March 16). Risks of Xylazine Use and Withdrawal in People Who Use Drugs in Philadelphia [Health Alert]. Philadelphia Department of Public Health. ​
* Bimeda (2020) Product Information: XylaMed [Digital Image]. <https://www.bimedaus.com/PDF-Flip/index.html> ​
* Dasgupta, N., D’Orazio, J., Shover, C.L., Sue, K., Torruella, R.A., (2022, April 8). Responding to Xylazine in the Drug Supply [Webinar]. National Harm Reduction Coalition. <https://drive.google.com/file/d/1SjYvpgS2Mv98irdPierWkHYm_39irIN6/view>​
* Drug Enforcement Administration.(2020) Definitions: Xylazine. <https://www.deadiversion.usdoj.gov/drug_chem_info/Xylazine.pdf>​
* Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022 Apr 1;233:109380. doi: 10.1016/j.drugalcdep.2022.109380. Epub 2022 Feb 26. PMID: 35247724; PMCID: PMC9128597.​ Pascale-Prieto A. Drug adulterants and their effects on the health of users: a critical review. OAS/CICAD and Plan Colombo, eds. Washington, D.C.; 2019. Final ENG Drug adulterants and their effects on the health of users - a ..\_.pdf (oas.org)
* Singh VM, Browne T, Montgomery J. The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid Crisis. Public Health Reports. 2020;135(1):6-10. doi:10.1177/0033354919887741
* Torruella, R.A. Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy 6, 7 (2011). <https://doi.org/10.1186/1747-597X-6-7>​